ITeos, GSK discontinue lung cancer therapy development-March 2024-www.financetom.com

ITeos, GSK discontinue lung cancer therapy development

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

ITeos, GSK discontinue lung cancer therapy development

May 26, 2025 6:40 AM

May 13 (Reuters) - iTeos Therapeutics ( ITOS ) and

partner GSK said on Tuesday that they terminated the

development of their experimental lung cancer therapy after its

failure to significantly improve progression free survival in a

mid-stage trial.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil

D'Silva)

Previous page： Vestas Wind Systems in talks with Tulsi Tanti and Dilip Shanghvi for controlling stake in Suzlon Energy Next page： Dilip Buildcon expects an uptick of order inflows in H2FY20

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Vestas Wind Systems in talks with Tulsi Tanti and Dilip Shanghvi for controlling stake in Suzlon Energy

Feb 22, 2019

Debt-laden Suzlon Energy is in talks with Danish firm, Vestas Wind Systems, for a control deal, sources privy to the developments told CNBC-TV18.

Dilip Buildcon expects an uptick of order inflows in H2FY20

Feb 22, 2019

Infrastructure major, Dilip Buildcon Ltd, on Friday said the company expects an uptick of order inflows in H2FY20.

Deloitte committed to high standards of corporate governance, says CEO Punit Renjen

Feb 22, 2019

Deloitte is very committed to high standards in terms of corporate governance, said Punit Renjen, CEO of the company, in...

SBI, PNB ready to infuse Rs 500 crore in emergency funding for Jet Airways, says report

Feb 22, 2019

State-owned banks State Bank of India (SBI) and Punjab National bank (PNB) have agreed to infuse Rs 500 crore in emergency funding to Jet Airways